This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma or Blood and Marrow Transplant (BMT)
and you are
between 18 and 75
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant approach for patients with advanced stage multiple myeloma.

Provided treatments

  • Procedure: Autologous peripheral blood stem cells (auto-PBSC) transplantation
  • Procedure: Allogeneic peripheral blood stem cells (allo-PBSC) transplantation
  • Drug: Filgrastim
  • Drug: Cyclophosphamide
  • Drug: Melphalan
  • Drug: Cyclosporine
  • Radiation: Total lymphoid irradiation
  • Biological: Rabbit anti-thymocyte globulin
  • Drug: Mycophenolate Mofetil 250mg
  • Drug: Solumedrol
  • Drug: Diphenhydramine
  • Drug: Acetaminophen
  • Drug: Hydrocortisone
Tris trial is registered with FDA with number: NCT00899847. The sponsor of the trial is Stanford University and it is looking for 9 volunteers for the current phase.
Official trial title:
A Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients